[2008: the end of rimonabant's story].
Paris
M
M
D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000266:history* / Q000627:therapeutic use; D013759:Dronabinol / Q000737:chemistry; D017277:Drug Approval; D005602:France; D049674:History, 21st Century; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects* / Q000266:history* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000266:history* / Q000627:therapeutic use; D043882:Receptors, Cannabinoid / Q000187:drug effects; D000077285:Rimonabant
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D013759:Dronabinol; D000077285:Rimonabant